{"id":"W2111872404","doi":"10.1517/14656566.2012.732998","title":"Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Incyte; Massachusetts Medical Society","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical trial; Janus kinase; Anemia; Internal medicine; Oncology; Tolerability; Adverse effect; Pharmacology; Bone marrow; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003045039,0.0002328739,0.0005258344,0.0003891113,0.0001064035,0.0004601532,0.0003644883,0.0006851217,0.004129112],"category_scores_gemma":[0.0005972904,0.0000608446,0.0003665183,0.0003158127,0.0001339465,0.0003470979,0.0001875127,0.000752071,0.001358875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000302963,"about_ca_system_score_gemma":0.000307854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000374142,"about_ca_topic_score_gemma":0.001073179,"domain_scores_codex":[0.9998517,0.00004716734,0.00001691474,0.00002186455,0.00004498418,0.00001733559],"domain_scores_gemma":[0.9998253,0.00006399716,0.00004276584,0.000002824043,0.00005204372,0.00001305606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005268249,0.00007127543,0.0004044908,0.009807431,0.0002158797,0.0005017964,0.00004612168,0.0004940138,0.004188131,0.001879566,0.1145222,0.8673422],"study_design_scores_gemma":[0.0005402513,0.0005223228,0.002682443,0.007650915,0.000613998,0.003362443,0.00006832846,0.0008078726,0.002507613,0.002950757,0.9782582,0.00003482595],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003394539,0.9766872,0.0009051587,0.009395297,0.001639937,0.00003590325,0.0002702107,0.0000472358,0.007624672],"genre_scores_gemma":[0.0444692,0.9354802,0.001218074,0.008226523,0.003830602,0.00007600903,0.0006623372,0.00001250648,0.006024493],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004129112,"threshold_uncertainty_score":0.01381326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1715041564346279,"score_gpt":0.4699678213059147,"score_spread":0.2984636648712869,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}